









Markets
/
Stocks
/
nasdaq-kalv
/

Kalvista Pharmaceuticals Inc

KALV

14.900USD

+0.500+3.47%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

753.09MMarket Cap

LossP/E TTM



Kalvista Pharmaceuticals Inc

14.900

+0.500+3.47%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Kalvista Pharmaceuticals Inc

Currency: USD Updated: 2026-02-06

Key Insights

Kalvista Pharmaceuticals Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 49 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 33.78.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Kalvista Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

49 / 392

Overall Ranking

156 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Kalvista Pharmaceuticals Inc Highlights

StrengthsRisks

KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drug therapies for diseases with significant unmet need. Its product candidate is sebetralstat, an inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Sebetralstat is designed to offer people living with HAE a medication that can be taken as a discreet oral dose to readily treat HAE attacks on-demand, including at the earliest signs before the attack fully develops. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its uncontrolled activity that drives HAE attacks. The Company is also designing an oral Factor XIIa inhibitor for HAE prophylaxis, positioning KalVista to address the full spectrum of HAE disease management. Factor XIIa inhibitor program is developed to address other therapeutic areas, including inflammation and thrombosis.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Fairly Valued

The company’s latest PE is -3.05, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 62.89M shares, decreasing 7.63% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 3.69K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.07.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

33.778

Target Price

+125.49%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Kalvista Pharmaceuticals Inc is 7.16, ranking 145 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.16

Change



Financials

7.07

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.14

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.98

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.61

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Kalvista Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Kalvista Pharmaceuticals Inc is 5.95, ranking 349 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.05, which is -55.84% below the recent high of -1.35 and -68.53% above the recent low of -5.14.

Score

Industry at a Glance

Previous score

5.95

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 49/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Kalvista Pharmaceuticals Inc is 8.89, ranking 40 out of 392 in the Biotechnology & Medical Research industry. The average price target is 30.00, with a high of 39.00 and a low of 22.00.

Score

Industry at a Glance

Previous score

8.89

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

33.778

Target Price

+125.49%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Kalvista Pharmaceuticals Inc

KALV

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Kalvista Pharmaceuticals Inc is 6.85, ranking 151 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 17.86 and the support level at 13.08, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.66

Change

0.19

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.221

Neutral

RSI(14)

46.221

Neutral

STOCH(KDJ)(9,3,3)

25.418

Sell

ATR(14)

0.935

Low Volatility

CCI(14)

-95.030

Neutral

Williams %R

72.016

Sell

TRIX(12,20)

-0.066

Sell

StochRSI(14)

31.852

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

15.304

Sell

MA10

15.277

Sell

MA20

15.474

Sell

MA50

15.528

Sell

MA100

13.779

Buy

MA200

13.537

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Kalvista Pharmaceuticals Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 124.42%, representing a quarter-over-quarter increase of 6.73%. The largest institutional shareholder is Steven Cohen, holding a total of 2.78M shares, representing 5.50% of shares outstanding, with 3967.78% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

VR Adviser, LLC

6.73M

Tang Capital Management, LLC

5.04M

+2.02%

Frazier Life Sciences Management, L.P.

5.02M

-0.35%

Suvretta Capital Management, LLC

4.77M

-3.76%

Capital World Investors

3.18M

Millennium Management LLC

2.96M

+17.10%

BlackRock Institutional Trust Company, N.A.

2.73M

-0.75%

The Vanguard Group, Inc.

Star Investors

2.49M

+3.32%

Medical Strategy GmbH

2.24M

-25.86%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Kalvista Pharmaceuticals Inc is 5.26, ranking 50 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is -0.33. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.